karin hehenberger swedish physician investor business executive diabetes known work field written numerous articles biotechnology published peer review journals worked executive different biotechnology companies investment firms faculty member department molecular medicine karolinska institute also obtained md phd molecular lectured topics autoimmune diseases diabetes molecular medicine industry challenges well provided commentary fox good morning america health new york usa hehenberger originally sweden played swedish national tennis age playing tennis internationally diagnosed type diabetes ending tennis career experience diabetes led pursue career fighting autoimmune hehenberger attended karolinska institutet stockholm sweden earned md phd molecular went postdoctoral fellowship joslin diabetes center harvard medical received kidney transplant father kidneys less percent total capacity received transplanted cadaver pancreas kidney surgery saved needing dialysis pancreas surgery rendered free diabetes longer needing inject hehenbergers career spent research business side medicine began career consultant mckinsey company consulted projects relating healthcare emphasis diabetes hehenberger also senior analyst two multibillion dollar hedgefunds us europe partner venture capital firm europe gaining experience public private also member senior management team eyetech pharmaceuticals helped take public hehenberger also previously vice president metabolic strategy business development johnson led johnson johnson metabolic task force responsible developing companys strategies metabolic disease efforts joined juvenile diabetes research foundation jdrf december senior vice president strategic alliances following time jdrf hehenberger served executive vice president scientific affairs chief medical coronado biosciences inc publicly traded biopharmaceutical company develops immunotherapy biologic agents autoimmune diseases career written articles peer review journals also panelist medical conferences including bioeurope massbio alliance regenerative medicine biopharm swedishamerican life science karin hehenberger sits board public swedish drug development company diamyd medical httpswwwdiamydcomdefaultaspx developing antigenspecific precision medicine immunotherapy prevention treatment type diabetes conducting registrational phase clinical trial united states europe httpsenwikipediaorgwikikarinmhehenberger